This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Conclusion/Depression and Its Subtypes: A Treatment Update

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

In this Supplement, Andrew A. Nierenberg, M.D., hasreviewed the large body of clinical trials that havedemonstrated a specific pharmacologic response for thedepressive subtype termed atypical depression, defined bythe presence of mood reactivity combined with 2 of thefollowing: hypersomnia, hyperphagia, leaden paralysis,and/or rejection sensitivity. For patients with this profileof depressive symptoms, the monoamine oxidase inhibitor(MAOI) phenelzine proved superior to the tricyclic antidepressant(TCA) imipramine. The combination of a welldefinedsymptom profile and evidence of a preferential responseto one class of antidepressants over another givesimportant support to the impetus to identify subtypes ofpatients with major depression.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)